Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: China-Based Global Healthcare Fund Invests Up to $10M in Global Healthcare Opportunities with China Market Potential

2 Apr

A China-based healthcare fund focuses on global growth opportunities. The company is based in Shanghai with additional offices in USA and China. In 2015, the firm launched a VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through this early-stage fund is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China, Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, healthcare IT and services. In terms of disease areas, The firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage. In the Diagnostics space, C-Bridge only looks for products in the commercial stage from China.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Firm Invests in USA & Taiwan-Based Early-Stage Medical Devices, Diagnostics, and Digital Health Companies

2 Apr

An early-stage venture capital firm based in Taiwan was formed by a group of successful entrepreneurs. The firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its latest fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firms open to either leading a financing round or joining a syndication. The firm is currently seeking opportunities from USA and Taiwan.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company for projects they led.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Actively Seeks Investment Opportunities in USA & Europe-Based Therapeutics, Devices, Diagnostics Companies

2 Apr

A venture capital firm based in Western Europe is investing from its most recent fund closed in 2016. The firm makes equity investments in life sciences and biomedical technology companies at all stages of development. However, the firm prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €4M to €10M. The firm looks for companies that are based in the US, Canada, Israel, and Europe. The firm is actively screening new investment opportunities.

The firm is generally opportunistic in the life sciences space. The firm targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and is open to all indications including orphan indications. In medical devices, the firm has a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The firm invests in companies at all stages of their development. For drug development, the firm invests from late preclinical to mid-stage clinical development. The firm sometimes considers companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan PE Firm Seeks New Investment Opportunities with Strongest Interest in Therapeutics, Devices, Digital Therapeutics

2 Apr

A private equity firm based in headquartered in Japan has a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, but may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine.  The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area, and invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor.  For early stage opportunities, the firm prefers that the company has a clinical trial plan in place.  While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate : Europe VC Invests in New Healthtech Platforms

5 Mar

A venture capital firm based in Switzerland has raised 4 funds to make equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 5 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe with a focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, medtech etc.. The firm focuses on companies developing biotech platforms, research tools and digital health startups. The firm will not invest in pure drug development companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, antibody development platforms and a technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate : Preventative Health Firm Opens Seed Fund to Invest in Reducing Healthcare Costs

5 Mar

A major provider of preventative and diagnostic services in Europe has a $50M seed stage fund through which they invest mainly in Seed to Series A companies across all geographies. The firms are separate entities and as an institutional venture capital firm, financial return is an important factor. However, because of this affiliation, the seend fund is able to leverage corporate benefits to support the growing needs of their portfolio companies. The firm has invested in Europe and the USA. Initial sizes of investment can largely vary, from $250K to 3M and a portion of their fund is reserved for follow-on investment.

Traditionally, the fund has been most interested in healthcare IT and services companies that address important problems in the healthcare industry, including reducing healthcare costs and improving patient outcomes. However, the firm has been pushing beyond healthtech and pursuing investments in the fields of diagnostics, genomics, and medtech. The firm is not interested in biotech.

The fund is able to leverage their relationship with the parent company to provide hands-on support for their portfolio companies. The firm is open to both leading and co-investing and has done both. The firm does not have specific requirements for the company or management team as long as they have compelling technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate : Shanghai Global Fund Invests in Heart and Eye Health

5 Mar

A healthcare focused fund, headquartered in Shanghai and with a presence in US and Europe is broadly focused in Life Sciences with strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, would like to lead investments and play active roles in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, and ophthalmology related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all opportunities within the early stage, however diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies that they have invested in. Outside of the board requirement, the firm is looking for strong management teams that demonstrate the capability to move their technology forwards.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: